Skip to main content
. 2016 Jan 13;17(1):149–161. doi: 10.1111/pme.12848

Table 4.

Clinical risk factors for development of postamputation chronic pain subtypes

Chronic Pain (cases) N = 80 Phantom Pain (cases) N = 72 RLP (cases) N = 76 RLP-Somatic (cases) N = 31 RLP-Neuro pathic (cases) N = 45 RLP-Neuroma (cases) N = 37 RLP-CRPS (cases) N = 15 RLP-Mosaic (cases) N = 8 Neuropathic Pain (All) N = 61
OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI)
[P] [P] [P] [P] [P] [P] [P] [P] [P]
Clinical Factor
PCS 13.39 (1.73−103.87) 6.20 (0.34–112.49) 3.05 (0.16–59.29) 0.48 (0.15–1.50) 2.71 (0.87–8.45) 2.47 (0.85–7.14) 1.82 (0.53–6.20) 1.08 (0.20–5.85) 3.78 (1.28–11.18)
[P value] [0.0016]* [0.1876] [0.5676] [0.194] [0.0735] [0.0899] [0.3474] [1.0000] [0.0103]*
PCL-M 10.08 (1.28–79.14) 1.72 (0.20–15.14) 2.31 (0.12–45.15) 0.19 (0.04–0.89) 6.92 (1.44–33.17) 6.67 (1.71–26.04) 7.13 (1.98–25.70) 0.58 (0.07–5.12) 9.28 (2.01–42.88)
[P value] [0.0099]* [1.0000] [1.0000] [0.0373]* [0.0088]* [0.0038]* [0.0029]* [1.0000] [0.0010]*
PHQ-9 2.40 (0.94–6.13) 9.13 (0.51–164.62) 4.46 (0.23–86.00) 0.38 (0.13–1.09) 3.53 (1.22–10.19) 3.72 (1.36–10.15) 4.59 (1.42–14.91) 0.71 (0.13–3.79) 4.46 (1.81–10.99)
[P value] [0.055] [0.0520] [0.3036] [0.0624] [ 0.0142]* [0.0081]* [0.010]* [1.0000] [0.0006]*
Regional Catheter 0.63 (0.30–1.33) 5.00 (0.58–42.80) 1.96 (0.19–19.70) 1.24 (0.50–3.12) 0.91 (0.37–2.25) 1.42 (0.58–3.51) 2.09 (0.67–6.49) 0.20 (0.02–1.71) 0.44 (0.21–0.92)
[P value] [0.227] [0.142] [1.0000] [0.6423] [0.8397] [0.4443] [0.2034] [0.142] [0.0269]*

The odds-ratios for development of chronic pain (all types), neuropathic pain, phantom limb pain, all types of residual limb pain, somatic residual limb pain, residual limb pain from presence of neuroma, complex regional pain syndrome, mosaic neuropathic residual limb pain and all neuropathic residual limb pain are reported above with P values in brackets. Factors associated with significant risk of a specific pain subtype (P value <0.05) are marked with an asterisk and italicized in bold. The data presented in the final column include total patients with neuropathic pain regardless of case or control status.